FDA
-
-
-
-
-
-
-
Organon presents tapinarof cream data across age groups at SPD meeting
-
-
-
-
-
-
-
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
-
-
-
-
-
-
-
Organon presents new VTAMA cream data showing early atopic dermatitis improvement
-
-
-
-
-
-
-
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
-
-
-
-
-
-
-
European Commission approves Henlius and Organon denosumab biosimilars
-
-
-
-
-
-
-
Organon (OGN) and Samsung Bioepis Granted FDA Interchangeability Designation
-
-
-
-
-
-
-
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Old
-
334,870 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


